The NPPA fixes the retail price of 11 formulations, Details


New Delhi: In a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India, set the retail price of 11 formulations, including those used to treat dry cough, high blood pressure and type 2 diabetes.

These include the antihypertensive drug Eris Lifescience, Telmisartan and the fixed dose drug Nebivolol, Akums, the fixed dose drug Telmisartan, Amlodipine and Hydrochlorathiazide (FDC) from Cadila Pharmaceutical which is used in the treatment of hypertension.

In addition to this, Agron Remedies, the anti-diabetic FDC of Glimeperide and Metformin HCL (SR) from Cadila and Windlas Biotech, the popular anti-diabetic treatment combination of Eris Lifescience, Glimeperide, Pioglitazone and Metformin HCL (SR) Tablet are also listed on the listing.

In addition, the list contains the drug combination of Dextromethorphan Hydrobromide and Chlorpheniramine Meleate Syrup from East Africa (India) Overseas / Cadila Pharmaceutical, which is used in the treatment of dry cough, Shiv Industries / Profic Organic’s Paracetamol plus Methocarbamol plus Diclofenac Potassium tablet combination, Akums / Cipla’s Vitamin D3 Oral Drops.

This pricing is followed by decisions taken by the National Pharmaceutical Prices Authority at its 89th meeting of the Authority held on June 28, 2021, during which the Authority discussed retail pricing. drugs listed.

In the exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with SO 1394 (E) of May 30, 2013 and SO 701 (E) of March 10, 2016 issued by the government of India within the Ministry of Chemicals and Fertilizers, National Pharmaceutical Pricing Authority (NPPA), hereby set the price as specified in column (6) of the table below as the price of detail, excluding tax on products and services, where applicable, in relation to the formulation specified in the corresponding entry in column (2) of said table with the dosage, unit and name of the manufacturer and the company of marketing, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

Sl.

No.

Formulation / brand name

name

Strength

Unity

Manufacturer and marketing company

Retail price

(Rs.)

(1)

(2)

(3)

(4)

(5)

(6)

1.

Telmisartan + Nebivolol tablet

Each uncoated bilayer tablet contains: Telmisartan IP 40 mg

Nebivolol hydrochloride IP

Equivalent to Nebivolol 5 mg

1

Tablet

M / s Eris Lifesciences Limited

13.61

2.

Glimeperide + Pioglitazone + Metformin HCL (SR) Tablet

Each uncoated bilayer tablet contains: Glimeperide IP 2 mg

Pioglitazone hydrochloride IP eq. to Pioglitazone 15mg

Metformin hydrochloride IP 1000 mg (as prolonged release)

1

Tablet

M / s Windlas Biotech Pvt. Ltd. / M / s Eris Lifesciences Limited

12.85

3.

Glimeperide + Pioglitazone + Metformin HCL (SR) Tablet

Each uncoated bilayer tablet contains: Glimeperide IP 1mg

Pioglitazone hydrochloride IP eq. to Pioglitazone 15mg

Metformin hydrochloride IP 1000mg (as

sustained-release form)

1

Tablet

M / s Windlas Biotech Pvt. Ltd. / M / s Eris Lifesciences Limited

8.73

4.

Glimeperide + Metformin HCL (SR) Tablet

Each uncoated tablet contains: Glimeperide IP 2mg

Metformin hydrochloride IP 1000mg (as

sustained-release form)

1

Tablet

M / s M / s Agron Remedies Private Limited / M / s Cadila

Pharmaceutical Ltd.

9.44

5.

Glimeperide + Metformin HCL (SR) Tablet

Each uncoated tablet contains: Glimeperide IP 1mg

Metformin hydrochloride IP 1000 mg (as prolonged release)

1

Tablet

M / s M / s Agron Remedies Private Limited / M / s Cadila

Pharmaceutical Ltd.

6.86

6.

Dextromethorphan hydrobromide + Chlorpheniramine

Meleate syrup

Each 5 ml contains:

Dextromethorphan hydrobromide IP 10 mg Chlorpheniramine meleate IP 2 mg

1 ML

M / s East Africa (India) Overseas / M / s Cadila

Pharmaceutical Ltd.

0.64

7.

Esomeprazole and Domperidone Prolonged-Release Capsule

Each hard gelatin capsule contains: Esomeprazole Magnesium IP eq. Esomeprazole 40 mg (as enteric coated lozenges),

Domperidone IP 30mg (as supported

release lozenges)

1

Capsule

M / s Skymap Pharmaceuticals Pvt. Ltd. / M / s Jagsonpal Pharmaceuticals Ltd.

10.20

8.

Telmisartan + Amlodipine + Hydrochlorathiazide Tablet

Each film-coated tablet contains: Telmisartan IP 40mg,

Amlodipine Besylate IP eq. to Amlodipine 5mg

1

Tablet

M / s Akums Drugs & Pharmaceuticals Ltd.

/ M / s Cadila Pharmaceuticals Ltd.

9.56

Sl.

No.

Formulation / brand name

name

Strength

Unity

Manufacturer and marketing company

Retail price

(Rs.)

(1)

(2)

(3)

(4)

(5)

(6)

Hydrochlorothiazide IP 12.50 mg

9.

Nebivolol hydrochloride

+ Telmisartan tablet

Each uncoated bilayer tablet contains: Nebivolol hydrochloride IP eq. to Nebivolol 5mg

Telmisartan IP 40mg

1

Tablet

M / s Windlas Biotech limited / M / s Eris Lifesciences Limited

13.61

ten.

Oral Vitamin D3 Drops

Each ml contains:

Cholecalciferol (Vitamin D3) IP 800IU

1 ML

M / s Akums Drugs & Pharmaceuticals Limited / M / s Cipla

Limit

5.06

11.

Paracetamol + Methocarbamol + Diclofenac Potassium

Tablet

Each film-coated tablet contains: Paracetamol IP 325 mg Methocarbamol IP 500 mg

Diclofenac Potassium BP 50mg tablet

1

Tablet

M / s Shiv Industries / M / s Profic Organic Limited

7.96

The notification further added;

(a) The manufacturer of the above mentioned formulations, i.e. “new drug” under paragraph 2 (u) of the DPCO, 2013 must set the retail price as specified in column ( 6) from the table above.

(b) The manufacturer may add the goods and services tax only if he has actually paid it or if it is payable to the government on the retail price mentioned in column (6) of said table above.

(c) The retail price of a package of the above formulation shall be determined by the relevant manufacturer in accordance with the retail price specified in column (6) of the above table in accordance with the provisions of paragraph 11 of the DPCO, 2013. The manufacturer must publish a price list in Form V form from the date of notification in accordance with paragraph 24 of the DPCO, 2013 to the NPPA through the IPDMS and submit a copy to the national drug controller and to the resellers.

(d) In accordance with subsection 24 (4) of the DPCO 2013, each retailer and dealer must post the price list and supplemental price list, if any, as supplied by the manufacturer, on a conspicuous part of the premises. where it operates in so as to be easily accessible to anyone wishing to consult them.

(e) The above mentioned retail price is only applicable to the above mentioned individual manufacturer / distributor i.e. who has requested it by submitting Form I for Fixing / price revision, as stipulated in the DPCO, 2013 and subject to compliance with all applicable legal requirements as defined by the government. under the relevant laws / rules, including the authorization of the manufacturing license of the competent authority, i.e. the central / state licensing authority, as appropriate, by the manufacturers / relevant marketing companies.

(f) In the event that the retail price of any of the above formulations is not met, in accordance with the instant price notification and ratings specified above, the relevant manufacturer / marketing company will be required to deposit the overbilled amount and interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

(g) Following the issuance of the ceiling price of such a formulation as specified in column (2) of the table above in this notification, the price order (s) fixing the ceiling price or the retail price, if applicable, issued before said above notification date, stand (s) replaced.


Leave a Reply

Your email address will not be published.